Waleed H. Hassanein Sells 8,625 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) Stock

TransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein sold 8,625 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the completion of the transaction, the chief executive officer now owns 61,643 shares of the company’s stock, valued at $9,457,269.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

TransMedics Group Stock Down 0.1 %

Shares of TMDX opened at $155.96 on Thursday. The company has a debt-to-equity ratio of 2.67, a current ratio of 9.37 and a quick ratio of 8.48. The stock has a market capitalization of $5.14 billion, a price-to-earnings ratio of -458.71 and a beta of 1.99. TransMedics Group, Inc. has a 1 year low of $36.42 and a 1 year high of $177.37. The business’s 50 day simple moving average is $154.75 and its 200-day simple moving average is $128.18.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.14. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. The company had revenue of $114.30 million for the quarter, compared to analysts’ expectations of $98.84 million. During the same quarter in the previous year, the business posted ($0.03) earnings per share. TransMedics Group’s quarterly revenue was up 117.7% on a year-over-year basis. As a group, equities analysts expect that TransMedics Group, Inc. will post 1.23 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. raised its position in TransMedics Group by 1.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 253,517 shares of the company’s stock valued at $20,010,000 after purchasing an additional 4,343 shares during the period. Envestnet Portfolio Solutions Inc. raised its holdings in TransMedics Group by 68.8% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 6,261 shares of the company’s stock valued at $494,000 after buying an additional 2,551 shares during the period. Principal Financial Group Inc. lifted its position in TransMedics Group by 21.3% in the fourth quarter. Principal Financial Group Inc. now owns 21,929 shares of the company’s stock worth $1,731,000 after buying an additional 3,858 shares during the last quarter. Level Four Advisory Services LLC purchased a new position in TransMedics Group during the fourth quarter worth $471,000. Finally, Dynamic Technology Lab Private Ltd bought a new position in TransMedics Group during the fourth quarter valued at $889,000. Institutional investors own 99.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Canaccord Genuity Group lifted their target price on shares of TransMedics Group from $117.00 to $169.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. Cantor Fitzgerald started coverage on TransMedics Group in a research report on Thursday, June 6th. They issued an “overweight” rating and a $161.00 price objective on the stock. Oppenheimer increased their target price on TransMedics Group from $125.00 to $200.00 and gave the stock an “outperform” rating in a research report on Thursday, August 1st. Morgan Stanley boosted their price target on TransMedics Group from $104.00 to $145.00 and gave the stock an “equal weight” rating in a report on Monday, July 15th. Finally, TD Cowen increased their price objective on shares of TransMedics Group from $130.00 to $175.00 and gave the company a “buy” rating in a report on Friday, June 7th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $171.44.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.